Chinese Alzheimer's drugmaker says lack of funding, Covid outbreak forced it to shutter international PhIII
Green Valley Pharma, the Shanghai drugmaker that scored a stunning approval to market an Alzheimer’s drug in China two years ago, has shuttered a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
